NextCure, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$57.6M | -$59.7M | -$67.6M | -$75.9M | -$70.8M |
| Operating expenses | $57.6M | $59.7M | $67.6M | $75.9M | $70.8M |
| Cash from operations | -$49.6M | -$40.8M | -$53.0M | -$53.9M | -$57.3M |
| Capital expenditure | — | $474,000 | $820,000 | $2.1M | $2.4M |
| Free cash flow | — | -$41.3M | -$53.8M | -$56.0M | -$59.6M |
| Impairments | — | $1.8M | — | — | — |
| Total assets | $50.2M | $80.9M | $128.0M | $184.2M | $242.4M |
| Total liabilities | $15.2M | $15.4M | $13.6M | $16.6M | $9.0M |
Shares outstanding 3.6M · Free float 55.5%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.